TherapeuticsMD
TXMD
140 hedge funds and large institutions have $711M invested in TherapeuticsMD in 2018 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 33 closing their positions.
52% more capital inflows, than outflows
Capital inflows: $109M | Capital outflows: $71.3M
15% more call options, than puts
Call options by funds: $1.92M | Put options by funds: $1.67M
2.16% more ownership
Funds ownership: 76.25% → 78.41% (+2.2%)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
9% less funds holding
Funds holding: 154 → 140 (-14)
33% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.5M |
| 2 |
Millennium Management
New York
|
+$11.9M |
| 3 |
Daruma Capital Management
New York
|
+$8.88M |
| 4 |
J. Goldman & Co
New York
|
+$7.75M |
| 5 |
Rubric Capital Management (New York)
New York
|
+$7.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.5M |
| 2 |
Nexthera Capital
New York
|
-$8.58M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.4M |
| 4 |
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$4.92M |
| 5 |
First Eagle Investment Management
New York
|
-$4.84M |
TXMD Hedge Fund Activity: Q4 2018 in Review
140 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2018, worth a combined $711M — down 39% from $1.17B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of TXMD and 22 opened new positions — a net loss of 11 holders — while 43 trimmed existing stakes and 47 added.
The largest buyer was Fidelity Investments, adding an estimated $29.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $18.5M.
- 140 institutional investors held TherapeuticsMD (TXMD) as of Q4 2018, down from 154 in Q3 2018.
- Funds reported $711M of TherapeuticsMD stock for Q4 2018, down 39% quarter-over-quarter.
- 22 funds opened new TherapeuticsMD positions in Q4 2018 and 33 closed out, a net change of -11 holders.
- The largest TherapeuticsMD buyer in Q4 2018 was Fidelity Investments, an estimated $29.5M added.
- The largest TherapeuticsMD seller in Q4 2018 was T. Rowe Price Associates, an estimated $18.5M sold.
Based on aggregated 13F filings for Q4 2018.